Aluoja Anu, Tõru Innar, Raag Mait, Eller Triin, Võhma Ülle, Maron Eduard
a Department of Psychiatry , University of Tartu , Tartu , Estonia.
b Institute of Family Medicine and Public Health, University of Tartu , Tartu , Estonia.
Nord J Psychiatry. 2018 Jul;72(5):354-360. doi: 10.1080/08039488.2018.1465590. Epub 2018 Apr 24.
Selective serotonin re-uptake inhibitors (SSRI) have proven to be effective in treatment of depression. Still, treatment efficacy varies significantly from patient to patient and about 40% of patients do not respond to initial treatment. Personality traits have been considered one source of variability in treatment outcome.
Current study aimed at identifying specific personality traits that could be predictive of treatment response and/or the dynamics of symptom change in depressive patients.
In a sample of 132 outpatients with major depressive disorder (MDD) treated with an SSRI-group antidepressant escitalopram, the Swedish universities Scales of Personality (SSP) were used in order to find predictive personality traits. For the assessment of the severity of depressive symptoms and the improvement rates, the Hamilton Depression Scale (HAM-D) and Montgomery-Åsberg Depression Rating Scale (MADRS) were used.
Escitalopram-treated MDD patients with higher social desirability achieved more rapid decrease in symptom severity. None of the studied traits predicted the end result of the treatment.
The findings suggest that specific personality traits may predict the trajectory of symptom change rather than the overall improvement rate.
选择性5-羟色胺再摄取抑制剂（SSRI）已被证明在治疗抑郁症方面有效。然而，治疗效果在患者之间差异显著，约40%的患者对初始治疗无反应。人格特质被认为是治疗结果变异性的一个来源。
当前研究旨在识别可预测抑郁症患者治疗反应和/或症状变化动态的特定人格特质。
在132名使用SSRI类抗抑郁药艾司西酞普兰治疗的重度抑郁症（MDD）门诊患者样本中，使用瑞典大学人格量表（SSP）来寻找预测性人格特质。为评估抑郁症状的严重程度和改善率，使用了汉密尔顿抑郁量表（HAM-D）和蒙哥马利-Åsberg抑郁评定量表（MADRS）。
具有较高社会赞许性的艾司西酞普兰治疗的MDD患者症状严重程度下降更快。所研究的特质均未预测治疗的最终结果。
研究结果表明，特定人格特质可能预测症状变化轨迹而非总体改善率。
